DuPont files NDA for ultrasound agent
DuPont Pharmaceuticals reported this month that it has submitted a new drug application (NDA) to the Food and Drug Administration for Definity, an ultrasound contrast agent formerly known as DMP 115, MRX 115, and Aerosomes. North Billerica, MA-based Du
DuPont Pharmaceuticals reported this month that it has submitted a new drug application (NDA) to the Food and Drug Administration for Definity, an ultrasound contrast agent formerly known as DMP 115, MRX 115, and Aerosomes. North Billerica, MA-based Du Pont hopes Definity will be the first multiuse contrast agent, with applications for both echocardiography and abdominal ultrasound.
For cardiac ultrasound, Definity would enhance ultrasound imaging of cardiac structure and functioning. For abdominal ultrasound, the agent would improve imaging of the liver and kidney. DuPont based its NDA on seven multicenter U.S. clinical trials, which included more than 600 patients.
